Dr. Lane is a nationally recognized expert in the medical management of osteoporosis and osteoarthritis. She is an associate editor for Seminars in Rheumatic Diseases, Rheumatology, and Arthritis Research and Therapy; an editorial board member for Journal of Bone and Mineral Research, Journal of Rheumatology and consultant editor for Annals of Internal Medicine, and Journal of Bone and Joint Surgery. Dr. Lane is affiliated with the Department of Epidemiology and Biostatistics, Division of Clinical Trials and Multicenter Studies, University of California, San Francisco, and is a collaborating researcher with the San Francisco Coordinating Center. Dr. Lane is a fully funded NIH researcher on osteoporosis, bone health, and osteoarthritis. Dr. Lane was awarded a mid career mentoring award from the NIH and welcomes junior faculty and graduate students who investigate the epidemiology and treatment of musculoskeletal diseases to the work in her group.

Research Interests

• Osteoarthritis
• Osteoporosis

Selected Publications

1. Cosman F, Lane NE, Bolognese M, Zanchetta J, Pedro A Garcia-Hernancez, Karen Sees, Kim Gaumer, Peter E Daddona. Transdermal Administration of PTH(1-34): Effects in Postmenopausal Women with Osteoporosis over 6 Months. J Clin Endocrinol Metab 2009 Oct;94(10):3772-80.
2. Lane NE, Nevitt MC, Lui LY, de Leon P, Corr M. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007 Sep 28;56(10):3319-3325.
3. Lane NE, Lian K, Nevitt MC, Zmuda JM, Lui L, Li J, Wang J, Fontecha M, Umblas N, Rosenbach M, de Leon P, Morr C. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum 54(4):1246-1254, 2006.
4. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006; 21(3):466-76.
5. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354(8):795-808.
6. Kelman A, Lui L, Yao W, Krumme A, Nevitt M, Lane NE. Association of higher levels of serum cartilage oligomeric matrix protein and n-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 2006; 54(1): 236-243.
7. Lane NE, Yao W, Nakamura MC, Humphrey MD, Kimmel D, Huang X, Sheppard D, Ross FP, Teitelbaum SL. Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J Bone Miner Res 2005; 20(1): 58-66.
8. Lane NE, Pierini E, Modin G, Sanchez S, Arnaud CD. Bone mass continues to increase after parathyroid hormone treatment is stopped in osteoporotic women on low dose corticosteroids and hormone replacement. Journal of Bone and Mineral Research 2000; 15(5):944-951.
9. Lane NE, Lin P, Christianson L, Gore LB, Nevitt MC. Mild acetabular dysplasia and the development of hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2000; 43(2):400-04.
10. Lane, NE, Sanchez, S, Modin, G, and Arnaud, C. Parathyroid hormone treatment can reverse steroid-induced bone loss. JCI 1998; 102(8):1627-1633.